These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24332053)

  • 21. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
    Schirripa M; Bergamo F; Cremolini C; Casagrande M; Lonardi S; Aprile G; Yang D; Marmorino F; Pasquini G; Sensi E; Lupi C; De Maglio G; Borrelli N; Pizzolitto S; Fasola G; Bertorelle R; Rugge M; Fontanini G; Zagonel V; Loupakis F; Falcone A
    Br J Cancer; 2015 Jun; 112(12):1921-8. PubMed ID: 25942399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Screening for K-ras mutations in colorectal and lung cancers by using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing].
    Zhang HP; Fu L; Chen PQ; Ye YB; Ji TH; Zheng LM
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):757-61. PubMed ID: 21215167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.
    Yu S; Xiao X; Lu J; Qian X; Liu B; Feng J
    PLoS One; 2013; 8(7):e68022. PubMed ID: 23874486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
    Freeman DJ; Juan T; Reiner M; Hecht JR; Meropol NJ; Berlin J; Mitchell E; Sarosi I; Radinsky R; Amado RG
    Clin Colorectal Cancer; 2008 May; 7(3):184-90. PubMed ID: 18621636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified mismatch polymerase chain reaction-restriction fragment length polymorphism detected mutations in codon 12 and 13 of exon 2 of K-
    Faleel FD; Zoysa MI; Lokuhetti MD; Gunawardena YI; Chandrasekharan VN; Dassanayake RS
    J Cancer Res Ther; 2016; 12(4):1272-1277. PubMed ID: 28169239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for brain metastases in patients with metastatic colorectal cancer.
    Christensen TD; Palshof JA; Larsen FO; Høgdall E; Poulsen TS; Pfeiffer P; Jensen BV; Yilmaz MK; Christensen IJ; Nielsen D
    Acta Oncol; 2017 May; 56(5):639-645. PubMed ID: 28447565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.
    Udar N; Lofton-Day C; Dong J; Vavrek D; Jung AS; Meier K; Iyer A; Slaughter R; Gutekunst K; Bach BA; Peeters M; Douillard JY
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):2001-2010. PubMed ID: 30019318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer.
    Sefrioui D; Sarafan-Vasseur N; Beaussire L; Baretti M; Gangloff A; Blanchard F; Clatot F; Sabourin JC; Sesboüé R; Frebourg T; Michel P; Di Fiore F
    Dig Liver Dis; 2015 Oct; 47(10):884-90. PubMed ID: 26160500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical relevance of the K-ras oncogene in colorectal cancer: experience in a Mexican population].
    Cabrera-Mendoza F; Gainza-Lagunes S; Castañeda-Andrade I; Castro-Zárate A
    Rev Gastroenterol Mex; 2014; 79(3):166-70. PubMed ID: 25216999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS.
    Yang J; Guo X; Wang M; Ma X; Ye X; Lin P
    Sci Rep; 2017 Dec; 7(1):17166. PubMed ID: 29215037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer.
    Netter J; Lehmann-Che J; Lambert J; Tallet A; Lourenco N; Soliman H; Bertheau P; Pariente B; Chirica M; Pocard M; Allez M; De The H; Gornet JM
    Bull Cancer; 2015 Feb; 102(2):117-25. PubMed ID: 25609485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer.
    Dotan E; Meropol NJ; Zhu F; Zambito F; Bove B; Cai KQ; Godwin AK; Golemis EA; Astsaturov I; Cohen SJ
    Br J Cancer; 2012 Feb; 106(4):748-55. PubMed ID: 22240781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Standard Chemotherapy with Bevacizumab as First-Line Therapy for Metastatic Colorectal Cancer with RAS Mutation].
    Yoshimatsu K; Satake M; Sano M; Asaka S; Yamada Y; Okayama S; Yano Y; Yokomizo H; Usui T; Yamaguchi K; Shiozawa S; Shimakawa T; Katsube T; Sagawa M; Naritaka Y
    Gan To Kagaku Ryoho; 2017 Oct; 44(10):918-920. PubMed ID: 29066695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping.
    Beau-Faller M; Legrain M; Voegeli AC; Guérin E; Lavaux T; Ruppert AM; Neuville A; Massard G; Wihlm JM; Quoix E; Oudet P; Gaub MP
    Br J Cancer; 2009 Mar; 100(6):985-92. PubMed ID: 19293811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
    Zeng Q; Xie L; Zhou N; Liu M; Song X
    Mol Diagn Ther; 2017 Aug; 21(4):443-451. PubMed ID: 28247181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High levels of D-dimer correlated with disease status and poor prognosis of inoperable metastatic colorectal cancer patients treated with bevacizumab.
    Zhu L; Liu B; Zhao Y; Liu L; Yang C; Yang Y; Zhong H
    J Cancer Res Ther; 2014 Dec; 10 Suppl():246-51. PubMed ID: 25693928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
    Osumi H; Shinozaki E; Suenaga M; Matsusaka S; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Mise Y; Ishizawa T; Inoue Y; Takahashi Y; Saiura A; Uehara H; Mun M; Okumura S; Mizunuma N; Miki Y; Yamaguchi T
    Int J Cancer; 2016 Aug; 139(4):803-11. PubMed ID: 27004837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer.
    Geido E; Sciutto A; Rubagotti A; Oliani C; Monaco R; Risio M; Giaretti W
    Cytometry; 2002 Aug; 50(4):216-24. PubMed ID: 12210601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?
    Selcukbiricik F; Bilici A; Tural D; Erdamar S; Soyluk O; Buyukunal E; Demirelli F; Serdengecti S
    Tumour Biol; 2013 Aug; 34(4):2233-9. PubMed ID: 23625655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer.
    Schimanski CC; Moehler M; Gockel I; Zimmermann T; Lang H; Galle PR; Berger MR
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1139-45. PubMed ID: 21468700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.